The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Kidney Cancer Therapeutics Market Research Report 2025
Synopsis
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
The global Kidney Cancer Therapeutics market was valued at US$ 422.9 million in 2023 and is anticipated to reach US$ 547 million by 2030, witnessing a CAGR of 3.8% during the forecast period 2024-2030.
The kidney cancer therapeutics market is evolving rapidly to address the treatment needs of patients diagnosed with kidney cancer, also known as renal cell carcinoma (RCC). This market encompasses a range of therapies, including targeted therapies, immunotherapies, and combination treatments. The increasing incidence of kidney cancer, advancements in understanding its molecular basis, and the emergence of novel treatment options are driving market growth. Targeted therapies that inhibit specific pathways implicated in kidney cancer progression, along with immunotherapies that harness the immune system's response, are gaining prominence. As research continues and personalized treatment approaches gain traction, the kidney cancer therapeutics market is expected to expand, offering new hope for improved outcomes and quality of life for patients with this challenging disease.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Therapeutics.
Report Scope
The Kidney Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Bristol-Myers Squibb
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Bayer
Exelixis
Eisai
Segment by Type
Surgery
Immunotherapy
Targeted Therapy
Other
Segment by Application
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Kidney cancer is cancer that begins in the kidneys. Your kidneys are two bean-shaped organs, each about the size of your fist. They're located behind your abdominal organs, with one kidney on each side of your spine. In adults, renal cell carcinoma is the most common type of kidney cancer.
The global Kidney Cancer Therapeutics market was valued at US$ 422.9 million in 2023 and is anticipated to reach US$ 547 million by 2030, witnessing a CAGR of 3.8% during the forecast period 2024-2030.
The kidney cancer therapeutics market is evolving rapidly to address the treatment needs of patients diagnosed with kidney cancer, also known as renal cell carcinoma (RCC). This market encompasses a range of therapies, including targeted therapies, immunotherapies, and combination treatments. The increasing incidence of kidney cancer, advancements in understanding its molecular basis, and the emergence of novel treatment options are driving market growth. Targeted therapies that inhibit specific pathways implicated in kidney cancer progression, along with immunotherapies that harness the immune system's response, are gaining prominence. As research continues and personalized treatment approaches gain traction, the kidney cancer therapeutics market is expected to expand, offering new hope for improved outcomes and quality of life for patients with this challenging disease.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Therapeutics.
Report Scope
The Kidney Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Bristol-Myers Squibb
Pfizer
Roche
Amgen
Aveo Pharmaceuticals
Bayer
Exelixis
Eisai
Segment by Type
Surgery
Immunotherapy
Targeted Therapy
Other
Segment by Application
Renal Cell Carcinoma
Renal Pelvis Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Surgery
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Kidney Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Renal Cell Carcinoma
1.3.3 Renal Pelvis Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer Therapeutics Market Perspective (2019-2030)
2.2 Kidney Cancer Therapeutics Growth Trends by Region
2.2.1 Global Kidney Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney Cancer Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Kidney Cancer Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Kidney Cancer Therapeutics Market Dynamics
2.3.1 Kidney Cancer Therapeutics Industry Trends
2.3.2 Kidney Cancer Therapeutics Market Drivers
2.3.3 Kidney Cancer Therapeutics Market Challenges
2.3.4 Kidney Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer Therapeutics Players by Revenue
3.1.1 Global Top Kidney Cancer Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Kidney Cancer Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Kidney Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer Therapeutics Revenue
3.4 Global Kidney Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Kidney Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Therapeutics Revenue in 2023
3.5 Kidney Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Kidney Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Kidney Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer Therapeutics Breakdown Data by Type
4.1 Global Kidney Cancer Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Kidney Cancer Therapeutics Forecasted Market Size by Type (2025-2030)
5 Kidney Cancer Therapeutics Breakdown Data by Application
5.1 Global Kidney Cancer Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Kidney Cancer Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney Cancer Therapeutics Market Size (2019-2030)
6.2 North America Kidney Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney Cancer Therapeutics Market Size by Country (2019-2024)
6.4 North America Kidney Cancer Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer Therapeutics Market Size (2019-2030)
7.2 Europe Kidney Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney Cancer Therapeutics Market Size by Country (2019-2024)
7.4 Europe Kidney Cancer Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Kidney Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer Therapeutics Market Size (2019-2030)
9.2 Latin America Kidney Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney Cancer Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Kidney Cancer Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Kidney Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Kidney Cancer Therapeutics Introduction
11.1.4 Merck Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Kidney Cancer Therapeutics Introduction
11.2.4 Novartis Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Kidney Cancer Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Kidney Cancer Therapeutics Introduction
11.4.4 Pfizer Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Kidney Cancer Therapeutics Introduction
11.5.4 Roche Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Kidney Cancer Therapeutics Introduction
11.6.4 Amgen Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Aveo Pharmaceuticals
11.7.1 Aveo Pharmaceuticals Company Detail
11.7.2 Aveo Pharmaceuticals Business Overview
11.7.3 Aveo Pharmaceuticals Kidney Cancer Therapeutics Introduction
11.7.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.7.5 Aveo Pharmaceuticals Recent Development
11.8 Bayer
11.8.1 Bayer Company Detail
11.8.2 Bayer Business Overview
11.8.3 Bayer Kidney Cancer Therapeutics Introduction
11.8.4 Bayer Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.8.5 Bayer Recent Development
11.9 Exelixis
11.9.1 Exelixis Company Detail
11.9.2 Exelixis Business Overview
11.9.3 Exelixis Kidney Cancer Therapeutics Introduction
11.9.4 Exelixis Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.9.5 Exelixis Recent Development
11.10 Eisai
11.10.1 Eisai Company Detail
11.10.2 Eisai Business Overview
11.10.3 Eisai Kidney Cancer Therapeutics Introduction
11.10.4 Eisai Revenue in Kidney Cancer Therapeutics Business (2019-2024)
11.10.5 Eisai Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Kidney Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Surgery
Table 3. Key Players of Immunotherapy
Table 4. Key Players of Targeted Therapy
Table 5. Key Players of Other
Table 6. Global Kidney Cancer Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Kidney Cancer Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Kidney Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Kidney Cancer Therapeutics Market Share by Region (2019-2024)
Table 10. Global Kidney Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Kidney Cancer Therapeutics Market Share by Region (2025-2030)
Table 12. Kidney Cancer Therapeutics Market Trends
Table 13. Kidney Cancer Therapeutics Market Drivers
Table 14. Kidney Cancer Therapeutics Market Challenges
Table 15. Kidney Cancer Therapeutics Market Restraints
Table 16. Global Kidney Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Kidney Cancer Therapeutics Market Share by Players (2019-2024)
Table 18. Global Top Kidney Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2023)
Table 19. Ranking of Global Top Kidney Cancer Therapeutics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Kidney Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Kidney Cancer Therapeutics Product Solution and Service
Table 23. Date of Enter into Kidney Cancer Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Kidney Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Kidney Cancer Therapeutics Revenue Market Share by Type (2019-2024)
Table 27. Global Kidney Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Kidney Cancer Therapeutics Revenue Market Share by Type (2025-2030)
Table 29. Global Kidney Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Kidney Cancer Therapeutics Revenue Market Share by Application (2019-2024)
Table 31. Global Kidney Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Kidney Cancer Therapeutics Revenue Market Share by Application (2025-2030)
Table 33. North America Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Kidney Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Kidney Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Kidney Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Kidney Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Kidney Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Kidney Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Kidney Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Kidney Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Kidney Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Kidney Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Merck Company Detail
Table 49. Merck Business Overview
Table 50. Merck Kidney Cancer Therapeutics Product
Table 51. Merck Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 52. Merck Recent Development
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis Kidney Cancer Therapeutics Product
Table 56. Novartis Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Bristol-Myers Squibb Company Detail
Table 59. Bristol-Myers Squibb Business Overview
Table 60. Bristol-Myers Squibb Kidney Cancer Therapeutics Product
Table 61. Bristol-Myers Squibb Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 62. Bristol-Myers Squibb Recent Development
Table 63. Pfizer Company Detail
Table 64. Pfizer Business Overview
Table 65. Pfizer Kidney Cancer Therapeutics Product
Table 66. Pfizer Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. Roche Company Detail
Table 69. Roche Business Overview
Table 70. Roche Kidney Cancer Therapeutics Product
Table 71. Roche Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 72. Roche Recent Development
Table 73. Amgen Company Detail
Table 74. Amgen Business Overview
Table 75. Amgen Kidney Cancer Therapeutics Product
Table 76. Amgen Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 77. Amgen Recent Development
Table 78. Aveo Pharmaceuticals Company Detail
Table 79. Aveo Pharmaceuticals Business Overview
Table 80. Aveo Pharmaceuticals Kidney Cancer Therapeutics Product
Table 81. Aveo Pharmaceuticals Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 82. Aveo Pharmaceuticals Recent Development
Table 83. Bayer Company Detail
Table 84. Bayer Business Overview
Table 85. Bayer Kidney Cancer Therapeutics Product
Table 86. Bayer Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 87. Bayer Recent Development
Table 88. Exelixis Company Detail
Table 89. Exelixis Business Overview
Table 90. Exelixis Kidney Cancer Therapeutics Product
Table 91. Exelixis Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 92. Exelixis Recent Development
Table 93. Eisai Company Detail
Table 94. Eisai Business Overview
Table 95. Eisai Kidney Cancer Therapeutics Product
Table 96. Eisai Revenue in Kidney Cancer Therapeutics Business (2019-2024) & (US$ Million)
Table 97. Eisai Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Kidney Cancer Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Surgery Features
Figure 4. Immunotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Other Features
Figure 7. Global Kidney Cancer Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Kidney Cancer Therapeutics Market Share by Application: 2023 VS 2030
Figure 9. Renal Cell Carcinoma Case Studies
Figure 10. Renal Pelvis Cancer Case Studies
Figure 11. Other Case Studies
Figure 12. Kidney Cancer Therapeutics Report Years Considered
Figure 13. Global Kidney Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Kidney Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Kidney Cancer Therapeutics Market Share by Region: 2023 VS 2030
Figure 16. Global Kidney Cancer Therapeutics Market Share by Players in 2023
Figure 17. Global Top Kidney Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Therapeutics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Kidney Cancer Therapeutics Revenue in 2023
Figure 19. North America Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Kidney Cancer Therapeutics Market Share by Country (2019-2030)
Figure 21. United States Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Kidney Cancer Therapeutics Market Share by Country (2019-2030)
Figure 25. Germany Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Kidney Cancer Therapeutics Market Share by Region (2019-2030)
Figure 33. China Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Kidney Cancer Therapeutics Market Share by Country (2019-2030)
Figure 41. Mexico Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Kidney Cancer Therapeutics Market Share by Country (2019-2030)
Figure 45. Turkey Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Kidney Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Merck Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 48. Novartis Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 50. Pfizer Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 51. Roche Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 52. Amgen Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 53. Aveo Pharmaceuticals Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 54. Bayer Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 55. Exelixis Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 56. Eisai Revenue Growth Rate in Kidney Cancer Therapeutics Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
